 | | Vol. 11.39 – 8 October, 2020 |
| |
|
|
| Patient‐derived colon organoids were co‐cultured successfully within a self‐assembled vascular network, and it was found that the colon organoids grew significantly better in the platform under constant perfusion versus conventional static condition.
[Advanced Materials] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators demonstrated that the profibrotic cytokine transforming growth factor β selectively up-regulated fibroblast growth factor receptor 3 (FGFR3) and its ligand FGF9 to promote fibroblast activation and tissue fibrosis, leading to a prominent FGFR3 signature in the systemic sclerosis skin.
[Science Translational Medicine] |
|
|
|
| The authors report a fibrinogen and thrombin based coagulation system to construct an artificial ECM for selectively cutting-off the tumor metabolic flux.
[Nature Communications] |
|
|
|
| Researchers identified the dual function cytokine IL-33 as an orchestrator of the glioblastoma microenvironment that contributed to tumorigenesis.
[Nature Communications] |
|
|
|
| Scientists used peptide amphiphiles (PAs) to coassemble with and organize ECM proteins producing tunable 3D models of the tumor microenvironment. They included specific epitopes, PA nanofibers, and ECM macromolecules for the 3D culture of human ovarian cancer, endothelial, and mesenchymal stem cells.
[Science Advances] |
|
|
|
| The authors defined an extended role for an effective immune response, not just in direct killing of tumor cells, but in widescale remodelling of the tumor microenvironment to favor loss of ECM, elimination of cancer stem cells, and propagation of adaptive immunity.
[Cancer Immunology Research] |
|
|
|
| Investigators identified a constitutive mechanism of resistance to PARP inhibitor (PARPi). They report that the bone marrow microenvironment facilitates DNA double-strand break repair activity in leukemia cells to protect them against PARPi-mediated synthetic lethality.
[Cell Reports] |
|
|
|
| Scientists showed that, in addition to PI3K, WAVE3 tyrosine phosphorylation could also be achieved downstream of TGF-β and EGF and that WAVE3 tyrosine phosphorylation was required for its oncogenic activity.
[Oncogenesis] |
|
|
|
| In the absence of exogenous transforming growth factor-beta2 (TGFβ2), compared with control matrices, glucocorticoid-induced cell-derived matrices triggered non-Smad TGFβ2 signaling in human trabecular meshwork cells, correlated with overexpression/activity of structural ECM genes, matricellular genes, crosslinking genes/enzymes, and ECM turnover genes/enzymes.
[Scientific Reports] |
|
|
|
| The authors demonstrated that monocyte-derived macrophages exposed to neutrophil elastase released active matrix metalloproteinases, increased expression of pro-inflammatory cytokines TNFα, IL-1β, and IL-8, and reduced capacity to phagocytose bacteria.
[Scientific Reports] |
|
|
|
| Scientists investigated whether the combination of intratumoural oncolytic reovirus, followed by targeted blockade of PD-1 checkpoint inhibition and/or the immunomodulatory CD73/Adenosine system could enhance anti-tumor immunity.
[Molecular Therapy-Oncolytics] |
|
|
|
| Laboratory studies were carried out in human metastatic castration-resistant prostate cancer organoid cultures, prostate cancer cell lines, and mouse xenograft models. Results supported Dickkopf-1 as a contributor to the immunosuppressive tumor microenvironment of double-negative prostate cancer.
[Full Journal Title] |
|
|
|
|
| Scientists outline fibronectin splice variants and their functions, evaluate potential therapeutic strategies targeting or utilizing fibronectin, and conclude by discussing potential future directions to modulate fibronectin function in development and wound healing.
[Advanced Drug Delivery Reviews] |
|
|
|
| The authors discuss the role of exosomal lncRNAs in the crosstalk between tumor cells and the surrounding cells of the microenvironment.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| Investigators present current evidence from human and animal studies on integrin structure and molecular signaling, with particular emphasis on signal transduction in infants.
[Pediatric Research] |
|
|
|
|
| Arch Oncology, Inc. announced the expansion of AO-176’s clinical development into a Phase I/II chemotherapy combination trial for patients with select solid tumors. AO-176 is an anti-CD47 antibody with a potential best-in-class profile that works by blocking the “don’t eat me” signal and also by preferentially binding to tumor cells in their acidic microenvironment.
[Arch Oncology, Inc.] |
|
|
|
| Codiak BioSciences, Inc. announced the initiation of patient dosing in its Phase I/II clinical trial of exoSTING, a novel exosome therapeutic candidate engineered with the company’s engEx Platform and designed to deliver Codiak’s proprietary STING agonist specifically to tumor-resident antigen presenting cells in the tumor microenvironment.
[Codiak BioSciences, Inc.] |
|
|
|
|
| March 22 – March 24, 2021
Virtual |
|
|
|
|
|
| | The Francis Crick Institute – London, England, United Kingdom |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Moores Cancer Center, UC San Diego – La Jolla, California, United States |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
